|Bid||510.01 x 800|
|Ask||514.05 x 800|
|Day's Range||509.20 - 518.92|
|52 Week Range||328.13 - 664.64|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||18.84|
|Earnings Date||Feb 04, 2021 - Feb 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||673.17|
Let's see if Regeneron Pharmaceuticals (REGN) stock is a good choice for value-oriented investors right now from multiple angles.
Pipeline and regulatory updates take centerstage in the biotech sector as Regeneron (REGN) and Gilead Sciences (GILD), among others, provide updates on their pipeline candidates.
The FDA approves Alnylam's (ALNY) Oxlumo injection for subcutaneous use, to lower urinary oxalate levels in pediatric and adult patients with primary hyperoxaluria type 1.